All In Biotech

Drug Trial Radar · NCT06610682

A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma

A Trial to Evaluate Deoxyribonucleic) in BRAF (V-raf Murine Sarcoma Viral Oncogene Homolog B1)-Altered Glioma During Treatment With Plixorafenib Alone or With Retifanlimab

Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Apr 7, 2025

Primary completion

Jun 30, 2027

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Fore Biotherapeutics; Ivy Brain Tumor Foundation; Incyte Corporation
First posted
Sep 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigators will evaluate the sensitivity of ctDNA from plasma and CSF at baseline (defined as C1D1) and over time in response to treatment with plixorafenib alone or in combination with retifanlimab in patients with BRAF-V600E mutant glioma refractory to prior therapies.

Conditions

  • BRAF V600E Mutation

Interventions

  • PlixorafenibDrug

    Patients will start the study drug (plixorafenib 900mg daily 30 minutes after a full meal or meal supplement) 7-28 days post-operatively, when clinically stable. Patients will take the drug daily by mouth continuously for 28-day cycles until progressive disease or up to 24 cycles. MRI will be performed post-operatively (between surgery and start of study drug) for evaluation of measurable disease, at the beginning of Cycle 2, then at the beginning of every odd cycle. Blood and CSF samples will be obtained on day of surgery, C1D1 (baseline), pre-C2 (week 4) and with every odd cycle up to and including C7 and EOT.

  • RetifanlimabDrug

    Investigators will evaluate the sensitivity of ctDNA from plasma and CSF at baseline and over time in response to treatment with plixorafenib alone or in combination with retifanlimab in patients with BRAF-V600E mutant glioma refractory to prior therapies.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Detection rate of BRAF-V600E ctDNA in CSF and/or plasmaTime frame: surgery, baseline (C1D1) and pre-cycle 2 (week 4)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Johns Hopkins

    Baltimore, Maryland · Recruiting

  • NYU Langone Health Perlmutter Cancer Center Ambulatory Care Center

    New York, New York · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.